Detecting Somatic Mutations in Neurological Disorders With Targeted NGS

January 18, 2017

In this webinar, Dr. Jamuar discusses the optimal technique for the detection of somatic mosaicism. He evaluates the limitations of Sanger sequencing and highlights the advantages of targeted next-generation sequencing (NGS), sharing findings from his paper, Somatic Mutations in Cerebral Cortical Malformations that was published in the New England Journal of Medicine.

Webinar at a glance:

  • Learn about somatic mutations and threshold of detection. 
  • Understand the prevalence of somatic mutations in neurodevelopmental disease.
  • Evaluate an optimal technique for somatic mosaicism detection -Limitations of Sanger sequencing
  • Advantages of targeted NGS Presenter: Dr. Saumya Jamuar Consultant, Genetics Service KK Women's and Children's Hospital, Singapore

A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015.

Subscribe to the Illumina video channel 

View customer spotlight videos

View Illumina webinars

View Illumina product videos

View Illumina support videos

Share this article on